-
IntroducedFeb 27, 2025
-
Passed House
-
Passed Senate
-
Signed into Law
Individualized Investigational Treatments ; Authorizes certain actions by eligible facilities, manufacturers operating within eligible facilities, & eligible patients relating to individualized investigational treatments; authorizes health plans, third-party administrators, & governmental agencies to provide coverage for cost of individualized investigational drug, biological product, or device, or cost of certain services; limits liability; prohibits licensing boards, disciplinary subcommittees, & entities responsible for Medicare certification from taking certain actions against health care provider's license; prohibits certain persons from blocking or attempting to block eligible patient's access to individualized investigational drug, biological product, or device; provides construction.
Last Action See all actions
House • May 03, 2025: Indefinitely postponed and withdrawn from consideration
Latest Bill Text See all bill texts
Summary/Bill Text
Comments on HB 1333
Tweets
Whip Lists
Sponsors
Votes
Actions
- May 03, 2025 | House
- Indefinitely postponed and withdrawn from consideration
- Mar 05, 2025 | House
- Referred to Health Professions & Programs Subcommittee
- Referred to Budget Committee
- Referred to Health & Human Services Committee
- Now in Health Professions & Programs Subcommittee
- Mar 04, 2025 | House
- 1st Reading (Original Filed Version)
- Feb 27, 2025 | House
- Filed
Bill Texts
Documents